Federal Official Gazette
DIOPE/ANS NOTICE OF SEPTEMBER 8, 2026 – CANCELLATION OF THE REGISTRATION OF BRADSAÚDE S.A.
In a supplementary review of the previous week’s editions, an ANS notice was identified regarding the cancellation, at the operator’s request, of the registration of the health plan operator BRADSAÚDE S.A., ANS registration No. 30.194-9.
According to the company’s notice to the market, the measure is part of the business combination between Bradsaúde and Bradesco Saúde. Bradsaúde transferred its dental plan portfolio and its other operating assets and liabilities to Mediservice Operadora de Planos de Saúde, and no longer acts directly as an operating entity.
RULINGS ON TAX CONSULTATIONS (SOLUÇÕES DE CONSULTA) No. 3,049 AND No. 3,050, OF SEPTEMBER 11, 2026
The Federal Revenue Service published interpretations on the percentages applicable to the IRPJ and CSLL calculation base under the presumed profit regime for dental, hospital and diagnostic support and therapy services. In summary, the reduced percentages of 8% for IRPJ and 12% for CSLL depend on the activities actually qualifying as hospital services or diagnostic support and therapy services, on the provider being organized as a business entity (sociedade empresária), and on compliance with Anvisa’s sanitary rules. For general dental services, or where the requirements are not met, the 32% percentage applies.
Where there are activities subject to different percentages, revenues must be segregated.
https://www.in.gov.br/web/dou/-/solucao-de-consulta-n-3.049-de-11-de-setembro-de-26-731385445
ANS news
No new news items were published after the previous cut-off.
Open public consultations
- CP 176. Subject: preliminary recommendations against incorporating the technology covered by UAT No. 184 – Molecular DNA analysis; search for microdeletions by FISH (Fluorescent In Situ Hybridization); microsatellite instability (MSI), detection by PCR, paraffin block, DUT SUBITEM – 110.39 – Syndrome of chromosomal abnormalities not clinically recognizable (array). Deadline: September 21 to October 10, 2026.
- CP 177. Subject: preliminary recommendations against incorporating the technologies covered by UAT No. 205 – Implantation of a device for cardiac contractility modulation and UAT No. 209 – 21-gene test for genomic expression profiling of breast tumors. Deadline: September 9 to 28, 2026.
Scheduled public hearings
- AP 69. Subject: proposals to include the following technologies in the List of Health Procedures and Events (Rol):
Implantation of a device for cardiac contractility modulation, for the treatment of patients with symptomatic chronic heart failure (NYHA III–IV), refractory to optimized pharmacological treatment, with an ejection fraction between 25% and 45%, QRS complex <130 ms, and without indication for cardiac resynchronization therapy; and
21-gene test for genomic expression profiling of breast tumors, as support for therapeutic decision-making for patients with early-stage breast cancer (stages I, II and IIIA), hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and node-negative disease or node-positive disease with involvement of one to three lymph nodes.
Date: Sep 16, from 9 a.m. to 12 p.m. To take part in Public Hearing 69, registration is required by 5 p.m. on Sep 15, through the ANS portal. The recording will be available on the Agency’s website.
Open public calls for input
There are no open public calls for input.
Open public calls
There are no open public calls or targeted social participation processes.
Other news
ANS president says he advises friends to turn to the courts against health plans
Source: www1.folha.uol.com.br · read the full article
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.